GUCY2C/Guanylyl cyclase C hFc Chimera, Human
GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

Immobilized GUCY2C/Guanylyl cyclase C hFc Chimera, Human at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-GUCY2C Antibody, hFc Tag with the EC50 of 15.4ng/ml determined by ELISA.

GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

GUCY2C/Guanylyl cyclase C hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

The purity of GUCY2C/Guanylyl cyclase C hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.

GUCY2C/Guanylyl cyclase C hFc Chimera, Human

Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Z03912
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
GUCY2C/Guanylyl cyclase C (Ser24-Gln430)
Accession # P25092-1		 hFc
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Immobilized GUCY2C/Guanylyl cyclase C hFc Chimera, Human (Cat.No.: Z03912) at 5 μg/ml (100μl/Well) on the plate can bind Biotinylated Anti-GUCY2C Antibody, hFc Tag
Expression System HEK293
Theoretical Molecular Weight 72.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 85-115 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human
    • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

    Immobilized GUCY2C/Guanylyl cyclase C hFc Chimera, Human at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-GUCY2C Antibody, hFc Tag with the EC50 of 15.4ng/ml determined by ELISA.

  • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human
    • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

    GUCY2C/Guanylyl cyclase C hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

  • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human
    • GUCY2C/Guanylyl Cyclase C HFc Chimera, Human

    The purity of GUCY2C/Guanylyl cyclase C hFc Chimera, Human is greater than 95% as determined by SEC-HPLC.


Background
Target Background Guanylyl cyclase C (GUCY2C) has canonical centrality in defense of key intestinal homeostatic mechanisms, encompassing fluid and electrolyte balance, epithelial dynamics, antitumorigenesis, and intestinal barrier function. GUCY2C may represent a new target for anti-obesity pharmacotherapy.
Synonyms Guanylyl cyclase C; GC-C; STAR; GUCY2C; GUC2C; STA receptor; DIAR6; EC 4.6.1; GCC; GUC2CEC 4.6.1.2; MUCIL

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.